Grey Wolf Therapeutics, a biotechnology company spearheading a new therapeutic approach to immuno-oncology driven by targeted neoantigen generation, today announced the presentation of promising preclinical in vivo data on the company’s first-in-class inhibitors of ERAP1 at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
M:M News
Grey Wolf Therapeutics completes £10 million ($14 million) series A financing
Grey Wolf Therapeutics completes £10 million ($14 million) series A financing with Andera Partners and Canaan to fund development of immuno-oncology therapies…
Pathios Therapeutics and Sygnature Discovery sign a strategic and innovative partnership
Pathios Therapeutics and Sygnature Discovery sign a strategic and innovative partnership to develop first in class therapies in autoimmune disease and immuno-oncology
Pathios Therapeutics presents preclinical in vivo proof of concept data for small molecule GPR65 inhibitor in human PDX cancer model
Data highlights the ability of GPR65 inhibition to bring about a robust Type I/II interferon (IFN) gene signature and reduce tumor burden…